ERICA GIORDANO: Open Payments
NPI 1124653399 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,112 in 98 payments from 17 companies in 2025. Trend: 2023 $1,935 · 2024 $1,677 · 2025 $2,112
Food & beverage: $2,112
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $432 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 17 | $337 |
| Madrigal Pharmaceuticals | 7 | $205 |
| GENZYME CORPORATION | 7 | $199 |
| Janssen Biotech, Inc. | 9 | $183 |
| Gilead Sciences, Inc. | 7 | $145 |
| Celltrion USA Inc. | 6 | $136 |
| Lilly USA, LLC | 6 | $131 |
| PFIZER INC. | 5 | $79 |
| Ardelyx, Inc. | 3 | $67 |
Products named: XIFAXAN, DUPIXENT, REZDIFFRA, RINVOQ, TREMFYA, VEGZELMA, OMVOH, IBSRELA.
Industry payments across TX — which companies pay providers there.
